Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maxigen BiotechTPE:1783 +0.13%87 5-Year Yield-on-Cost % is 2.09 as of Aug. 02, 2026, which is 9% above its 10-year median of 1.92. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$59.41 (Significantly Undervalued). Among 319 Medical Devices & Instruments companies, Maxigen Biotech ranks worse than 55.17% on this metric.
Maxigen Biotech's yield on cost for the quarter that ended in Mar. 2026 was 2.09.
The historical rank and industry rank for Maxigen Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:1783'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.53 Med: 1.92 Max: 5.13
Current: 2.09
During the past 13 years, Maxigen Biotech's highest Yield on Cost was 5.13. The lowest was 0.53. And the median was 1.92.
TPE:1783's 5-Year Yield-on-Cost % is ranked worse than 55.17% of 319
companies
in the Medical Devices & Instruments industry
Industry Median: 2.44
vs TPE:1783: 2.09
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Maxigen Biotech 5-Year Yield-on-Cost % Related Terms
TPE:1783 vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Maxigen Biotech is calculated as
Maxigen Biotech (TPE:1783) has a 5-Year Yield-on-Cost % of 2.09 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Maxigen Biotech and its competitors. This is near median its historical median of 1.92. Over the past decade, Maxigen Biotech's 5-Year Yield-on-Cost % has ranged from 0.53 to 5.13. According to the industry distribution chart, Maxigen Biotech ranks #176 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 55.2%.
Is Maxigen Biotech's 5-Year Yield-on-Cost % too high?
Maxigen Biotech's current 5-Year Yield-on-Cost % of 2.09 is near median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 5.13. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.44. Maxigen Biotech's value of 2.09 is 14.3% below this industry median. Based on the distribution chart, Maxigen Biotech ranks #176 out of 319 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #176 out of 319 companies for 5-Year Yield-on-Cost %. This places Maxigen Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. Maxigen Biotech's value of 2.09 is 14.3% below this benchmark. Historically, Maxigen Biotech's own 5-Year Yield-on-Cost % has ranged from 0.53 to 5.13 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 2.44, Maxigen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current 5-Year Yield-on-Cost % of 2.09 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current 5-Year Yield-on-Cost % is 2.09, which is near median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.41, compared to a current price of NT$39.85 — trading 32.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.09, which is near median its 10-year median of 1.92 and 14.3% below the Medical Devices & Instruments industry median of 2.44. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current 5-Year Yield-on-Cost % is 2.09 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.85 is trading 32.9% below its estimated GF Value™ of NT$59.41.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
5-Year Yield-on-Cost %: 2.09 (near median its 10-year median of 1.92)
GF Value™: NT$59.41 vs. price of NT$39.85 (32.9% below fair value)
Industry Position: 14.3% below the Medical Devices & Instruments median (#176 of 319)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
